Formulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Delivery

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorKattar, Axel
dc.contributor.authorQuelle Regaldie, Ana
dc.contributor.authorSánchez Piñón, Laura
dc.contributor.authorConcheiro Nine, Ángel Joaquín
dc.contributor.authorÁlvarez Lorenzo, Carmen
dc.date.accessioned2023-04-19T06:30:55Z
dc.date.available2023-04-19T06:30:55Z
dc.date.issued2023
dc.description.abstractThe aim of this work was to develop niosomes for the ocular delivery of epalrestat, a drug that inhibits the polyol pathway and protects diabetic eyes from damage linked to sorbitol production and accumulation. Cationic niosomes were made using polysorbate 60, cholesterol, and 1,2-di-O-octadecenyl-3-trimethylammonium propane. The niosomes were characterized using dynamic light scattering, zeta-potential, and transmission electron microscopy to determine their size (80 nm; polydispersity index 0.3 to 0.5), charge (−23 to +40 mV), and shape (spherical). The encapsulation efficiency (99.76%) and the release (75% drug release over 20 days) were measured with dialysis. The ocular irritability potential (non-irritating) was measured using the Hen’s Egg Test on the Chorioallantoic Membrane model, and the blood glucose levels (on par with positive control) were measured using the gluc-HET model. The toxicity of the niosomes (non-toxic) was monitored using a zebrafish embryo model. Finally, corneal and scleral permeation was assessed with the help of Franz diffusion cells and confirmed with Raman spectroscopy. Niosomal permeation was higher than an unencapsulated drug in the sclera, and accumulation in tissues was confirmed with Raman. The prepared niosomes show promise to encapsulate and carry epalrestat through the eye to meet the need for controlled drug systems to treat the diabetic eyegl
dc.description.peerreviewedSIgl
dc.description.sponsorshipThis research was funded by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Actions (grant agreement-No 813440).gl
dc.identifier.citationPharmaceutics 2023, 15(4), 1247gl
dc.identifier.doi10.3390/pharmaceutics15041247
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10347/30459
dc.language.isoenggl
dc.publisherMDPIgl
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/813440gl
dc.relation.publisherversionhttps://doi.org/10.3390/pharmaceutics15041247gl
dc.rights© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).gl
dc.rights.accessRightsopen accessgl
dc.subjectNiosomegl
dc.subjectDiabetic eyegl
dc.subjectHET-CAMgl
dc.subjectZebrafishgl
dc.subjectEpalrestatgl
dc.subjectCationic lipidgl
dc.subject.classificationMaterias::Investigacióngl
dc.titleFormulation and Characterization of Epalrestat-Loaded Polysorbate 60 Cationic Niosomes for Ocular Deliverygl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublication017b2725-d3de-40d7-8859-18c50f038d1d
relation.isAuthorOfPublicationfbd9d3a4-b1f4-4aff-8472-de22b1c140c4
relation.isAuthorOfPublication44d6632e-65cd-485a-bb67-86df5567793a
relation.isAuthorOfPublication.latestForDiscovery017b2725-d3de-40d7-8859-18c50f038d1d

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pharmaceutics 2023, 15, 1247.pdf
Size:
2.81 MB
Format:
Adobe Portable Document Format
Description: